Aviado · Research
Longevity Daily
Thursday, June 4, 2026
Listen
Today's Brief
The first randomized, placebo-controlled evidence that a GLP-1 drug slows biological aging in human DNA puts semaglutide at the center of today's digest — and a separate NZ Herald deep-dive suggests the entire drug class may also suppress cancer, cementing GLP-1s as the most consequential longevity story of 2026. In the cognitive corner, a Psychology Today synthesis of Harvard and Danish population data makes a compelling case that low-dose lithium meaningfully reduces dementia risk. Metformin optimists should read carefully: a new analysis ties long-term use to elevated liver cancer risk — a significant evidence check. NewLimit's $435 million raise signals serious institutional conviction that epigenetic reprogramming is moving from concept to clinic.
10 stories2 peer-reviewed1 trials
Cognitive Health & Neuroprotection
Lithium Exposure Consistently Linked to Lower Dementia Rates -- Harvard Nature Paper Adds Weight
A Psychology Today synthesis of large Danish population studies -- combined with a landmark August 2025 Harvard Medical School paper published in Nature -- finds that lithium exposure is consistently associated with reduced dementia incidence, with the signal appearing dose-responsive across cohorts. The finding is no longer a curious side observation: the epidemiological pattern is now backed by mechanistic data showing lithium's capacity to inhibit tau phosphorylation and reduce neuroinflammation. If you're building a proactive cognitive health strategy, low-dose lithium is one of the most credible and underexplored interventions in the evidence base -- though dosing guidance from a clinician is essential.
Read more →Caveolin-1 Gene Therapy Cuts Brain Protein Aggregates Tied to ALS and LATE Dementia
Researchers applied a caveolin-1 gene therapy to a mouse model of TDP-43 pathology -- the protein aggregation mechanism underlying ALS and the recently named LATE (limbic-predominant age-related TDP-43 encephalopathy) dementia -- and found significant reductions in damaging brain aggregates. This follows earlier research showing the same gene therapy reduced Alzheimer's pathology, suggesting caveolin-1 may act as a broad neuroprotective target across several neurodegenerative diseases. Caveat: this is early-stage mouse research, but the convergence of TDP-43 pathology across multiple conditions makes the target genuinely important to watch.
Read more →Supplements & Compounds
32 Human Studies Later: Which Supplements Actually Support Healthy Aging?
A review published in Current Nutrition Reports synthesized 32 human studies on targeted nutrients for aging, finding the strongest and most consistent evidence for protein and collagen supplementation -- particularly when paired with resistance training -- for preserving muscle mass and physical function. NAD+ precursors, glycine, N-acetylcysteine, and antioxidants showed promising signals for mitochondrial efficiency and cognitive performance, though effect sizes varied significantly across populations and dosing protocols. The key takeaway: no single compound wins, but a personalized stack built around protein adequacy, mitochondrial support, and exercise integration has the clearest human evidence behind it.
Read more →Fisetin Clears Senescent Cells from Blood Vessels Damaged by Chemotherapy
New research shows fisetin -- the flavonoid senolytic found in strawberries -- selectively clears senescent cells from blood vessels prematurely aged by doxorubicin chemotherapy, reversing arterial stiffening and restoring vascular dilation capacity. The mechanism reinforces fisetin's identity as a senolytic rather than a simple antioxidant: it targets the specific damaged cells driving vascular dysfunction rather than just scavenging free radicals. While this is preclinical research, it strengthens fisetin's evidence profile for anyone interested in cardiovascular aging -- especially those who have undergone chemotherapy.
Read more →Research & Papers
First RCT Shows Semaglutide Slows Biological Aging Markers in Human DNA
A randomized, placebo-controlled trial -- the first of its kind -- found that semaglutide (the active ingredient in Ozempic and Wegovy) significantly reduced the accumulation of epigenetic aging markers in the DNA of adults with HIV compared to placebo. The mechanism -- reduced chronic inflammation and improved metabolic regulation -- is not specific to HIV, making the findings broadly relevant to anyone tracking or managing biological age. While the study population limits direct generalizability, this is the strongest human evidence yet that a GLP-1 drug can directly alter the pace at which your biology ages. For anyone already taking or considering GLP-1 therapy, this trial moves the conversation well beyond weight and glycemic control.
Read more →Metformin Tied to Higher Liver Cancer Risk -- Especially in Men and Long-Term Users
A new analysis in Gastroenterology Advisor finds metformin use is associated with a 22% elevated risk of hepatocellular carcinoma overall -- rising to 68% higher risk in users aged 60 and under, and 41% higher after more than five years of use. Men show a distinct risk signal (adjusted HR 1.22), and higher cumulative daily doses compound it further. This is a critical evidence check for anyone taking metformin off-label for longevity: the drug's risk-benefit profile is considerably more nuanced than the popular narrative suggests, and proactive liver monitoring looks increasingly warranted.
Read more →Harvard's New Genetic Clock Predicts Biological Age Across Humans, Primates, and Rodents
Harvard scientists have developed a genetic clock capable of predicting biological age and remaining lifespan across humans, non-human primates, and rodents -- the first to validate cross-species with this breadth. Cross-species consistency matters because it implies the underlying aging mechanisms are evolutionarily conserved, not quirks of one model organism, substantially boosting confidence in the clock's biological accuracy. For health optimizers tracking interventions through epigenetic or biological age metrics, more precise and validated measurement tools are the prerequisite for knowing whether anything you're doing is actually working.
Read more →Lifestyle & Nutrition
Oxford and Harvard Researchers Independently Confirm: These Habits Add a Decade of Healthy Life After 50
Separate research teams at Oxford and Harvard converged on the same cluster of lifestyle behaviors -- centering on physical activity, diet quality, sleep, and social connection -- that add roughly 10 years of healthy life expectancy after age 50. The independent replication across institutions and methodologies makes this one of the more robust findings in the longevity lifestyle literature. In an era of expensive biohacks and longevity clinics, it's a useful recalibration: the highest-leverage interventions remain free, accessible, and supported by decades of evidence.
Read more →Industry & Policy
NewLimit Raises $435 Million to Push Epigenetic Reprogramming Into the Clinic
Anti-aging biotech NewLimit has closed a $435 million fundraise -- backed by Kleiner Perkins, Founders Fund, Thrive Capital, and Eli Lilly -- to advance its first clinic-ready epigenetic reprogramming therapeutic candidate. Eli Lilly's participation is the most significant signal here: it marks one of the largest traditional pharma players making a direct bet on cellular reprogramming as a therapeutic category, not just a research curiosity. The company is expanding both computational and wet-lab operations, with the goal of transitioning its lead program toward human trials.
Read more →